Ro becomes medication management system
Ro
Ro is becoming a medication management system, not a video doctor app. That matters because the harder part of obesity, fertility, and hormone care is not the first consult, it is keeping the patient moving through labs, insurance checks, dose changes, refills, and follow ups for months. Ro built its intake, pharmacy, lab, and monitoring stack around that loop, which is why GLP-1s became its main growth engine and why the company now competes on retention and workflow, not on visit convenience alone.
-
The clearest proof is category mix. Ro grew to an estimated $598M annualized revenue in 2024, up from $360M in 2023, with GLP-1 obesity care scaling to about 40% of revenue while ED fell from being the core business to roughly one third. Chronic medication programs reward ongoing management, not one off consults.
-
Ro Body shows what the pathway product looks like in practice. Patients pay a monthly subscription for structured obesity care, then move through eligibility review, lab work, titration, side effect checks, fulfillment, and renewals. Ro added home diagnostics, phlebotomy, labs, and pharmacies so more of that workflow happens inside one system.
-
This is also how Ro differs from adjacent players. Hone built a similar recurring model around testosterone, where blood work and dosage changes drive retention. Noom, by contrast, pairs GLP-1 access with coaching and tracking. As branded GLP-1 pricing converges across Ro, Hims & Hers, and LifeMD, the real moat shifts to who runs the cleanest care loop.
The next step is for Ro to turn these condition specific loops into reusable infrastructure across more chronic categories and into employer, payer, and pharma channels. As drug access gets commoditized, the winners in telehealth will look less like virtual clinics and more like operating systems that keep treatment on track over time.